Isocratic reversed-phase HPLC for simultaneous separation and determination of seven antiepileptic drugs and two of their active metabolites in human plasma

被引:25
作者
Ma, Chun-Lai
Jiao, Zheng
Jie, Yang
Shi, Xiao-Jin
机构
[1] Fudan Univ, Huashan Hosp, Dept Pharm, Shanghai 200040, Peoples R China
[2] Nanjing Med Univ, Wuxi Hosp 1, Dept Pharm, Wuxi 214002, Peoples R China
关键词
column liquid chromatography; isocratic RP-LC; antiepileptic drugs in human plasma; zonisamide; oxcarbazepine; lamotrigine;
D O I
10.1365/s10337-006-0157-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple reversed-phase high-performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of the antiepileptic drugs (AEDs) zonisamide (ZNS), primidone (PRI), lamotrigine (LTG), phenobarbital (PB), phenytoin (PHT), oxcarbazepine (OXC), and carbamazepine (CBZ) and two of their active metabolites, monohydroxycarbamazepine (MHD) and carbamazepine 10,11-epoxide (CBZE) in human plasma. Plasma (100 mu L) was pretreated by deproteinization with 300 mu L methanol containing 20 mu g mL(-1) propranolol hydrochloride as internal standard. HPLC was performed on a C-8 column (4.6 mm x 250 mm; particle size 5 mu m) with methanol-acetonitrile-0.1% trifluoroacetic acid, 235:120:645 (v/v), as mobile phase at a flow rate of 1.5 mL min(-1). ZNS, OXC, and CBZ were monitored by UV detection at 235 nm, and PRI, LTG, MHD, PB, PHT, and CBZE by UV detection at 215 nm. Relationships between response and concentration were linear over the concentration ranges 1-80 mu g mL(-1) for ZNS, 5-50 mu g mL(-1) for PRI, 1-25 mu g mL(-1) for LTG, 1-50 mu g mL(-1) for MHD, 5-100 mu g mL(-1) for PB, 1-10 mu g mL(-1) for CBZE, 0.5-25 mu g mL(-1) for OXC, 1-50 mu g mL(-1) for PHT, and 1-25 mu g mL(-1) for CBZ. Intra-day and inter-day reproducibility were adequate (coefficients of variation were <= 11.6%) and absolute recovery ranged from 95.2 +/- 6.13 to 107.7 +/- 7.76% for all the analytes; for the 15 recovery was 98.69 +/- 1.12%. The method was proved to be accurate, reproducible, convenient, and suitable for therapeutic monitoring of the nine analytes.
引用
收藏
页码:267 / 275
页数:9
相关论文
共 31 条
[1]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[2]  
Baulac M., 2002, ANTIEPILEPTIC DRUGS, P514
[3]   Selection of antiepileptic drug polytherapy based on mechanisms of action: The evidence reviewed [J].
Deckers, CLP ;
Czuczwar, SJ ;
Hekster, YA ;
Keyser, A ;
Kubova, H ;
Meinardi, H ;
Patsalos, PN ;
Renier, WO ;
Van Rijn, CM .
EPILEPSIA, 2000, 41 (11) :1364-1374
[4]  
Eadie MJ, 2001, BRIT J CLIN PHARMACO, V52, p11S
[5]  
EMILIO P, 2006, BR J CLIN PHARM, V61, P246
[6]   SIMULTANEOUS DETERMINATION OF ANTIEPILEPTIC DRUGS AND THEIR METABOLITES, INCLUDING CHIRAL COMPOUNDS, VIA BETA-CYCLODEXTRIN INCLUSION COMPLEXES BY A COLUMN-SWITCHING CHROMATOGRAPHIC TECHNIQUE [J].
ETO, S ;
NODA, H ;
NODA, A .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 658 (02) :385-390
[7]   A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients [J].
Franceschi, L ;
Furlanut, M .
PHARMACOLOGICAL RESEARCH, 2005, 51 (04) :297-302
[8]  
GARNETT WR, 2005, APPL PHARMACOKINETIC, P491
[9]   Best practice in therapeutic drug monitoring [J].
Gross, AS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :95-99
[10]  
HOLMES GL, 2002, ANTIEPILEPTIC DRUGS, P285